I don’t know about Ord Minnett but Morningstar has had coverage of Avita for a few years now. I don’t think they provide analyst coverage of ARX.
To compare their view on AVH v PNV, Morningstar had an estimated fair value on AVH in early 2021 of $14.30. In May 2021, Ponraj lowered the estimated fair value for AVH to $7. He was unimpressed with the company’s flat growth in procedures. He described AVH as a no-moat, single-product, single-geography company with a long road to profitability. He believed Recell had a strong position in the outpatient burns market, but noted that the product was relatively less economical.
A year later, in June 2022, he seemed to have overcome his concerns about the company, now viewing AVH as “standout’ value @ $1.72. Measured against Morningstar’s estimated fair value of $14.30 in early 2021, I guess it was!
In August this year, Morningstar quant. had a fair value for AVH of $6.46 and Morningstar Premium a fair value of $5.60. AVH is currently trading at $4.45.
broker recommendation, page-265
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.64 |
Change
-0.010(0.38%) |
Mkt cap ! $1.823B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.64 | $2.58 | $2.297M | 877.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2375 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.64 | 3584 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |